Document is current
Any future updates will be listed below
-
Authors
,
Vogel, Jacob W. https://orcid.org/0000-0001-6394-9940
Young, Alexandra L.
Oxtoby, Neil P. https://orcid.org/0000-0003-0203-3909
Smith, Ruben https://orcid.org/0000-0001-7147-0112
Ossenkoppele, Rik
Strandberg, Olof T.
La Joie, Renaud https://orcid.org/0000-0003-2581-8100
Aksman, Leon M.
Grothe, Michel J. https://orcid.org/0000-0003-2600-9022
Iturria-Medina, Yasser https://orcid.org/0000-0002-9345-0347
Pontecorvo, Michael J. https://orcid.org/0000-0002-8419-7589
Devous, Michael D. https://orcid.org/0000-0002-6871-0063
Rabinovici, Gil D. https://orcid.org/0000-0002-3626-4265
Alexander, Daniel C. https://orcid.org/0000-0003-2439-350X
Lyoo, Chul Hyoung https://orcid.org/0000-0003-2231-672X
Evans, Alan C. https://orcid.org/0000-0003-3841-6098
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 20 August 2020
Accepted: 4 March 2021
First Online: 29 April 2021
Competing interests
: M.J.P. and M.D.D. are employees of AVID Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, and are minor stockholders in Eli Lilly and Company. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly and Company, Eisai, GE Healthcare, Pfizer and Roche. In the past two years, he has received consultancy/speaker fees from AC Immune, ALZpath, Biogen, Cerveau and Roche. The remaining authors declare no competing interests.
